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Generation of broadly neutralizing (bN) antibodies against the HIV envelope glycoprotein (Env) of 
HIV following immunization is one of the goals in HIV vaccine research, since such antibodies have 
been shown to offer protection in experimental HIV/SHIV models. Shortly after HIV infection, a rapid 
production of narrow neutralizing (nN) antibodies is induced by Env, while bN antibodies appear only 
in some individuals and several years post-infection. Similarly, attempts to elicit bN antibodies by 
vaccination often result in the production of non-, or narrow neutralizing antibodies, but not bN 
antibodies. 
The urge to understand the mechanism behind the production of nN over bN antibodies following 
immunization with Env prompted Dr. Andrew McGuire of the Stamatatos Lab in the Vaccine and 
Infectious Disease Division (VIDD) to investigate the matter. In a paper published last December 
in Science, Dr. McGuire led us through the story of the generation of neutralizing antibodies against 
HIV. "This study sheds some light onto why previous HIV vaccine efforts are skewing the immune 
response towards making non-protective antibody responses", commented Dr. McGuire. 
 The researchers studied the interactions of Env with B cell receptors, the progenitors of antibodies. 
The B cell receptors are antibody precursors expressed on the surface of naïve B cells.  When a B 
cell receptor recognizes a foreign antigen the B cell becomes activated, internalizes the antigen, and 
begins to divide and mutate the B cell receptor gene. This process occurs many times and the end 
result is a number of daughter B cells that secrete soluble version of the B cell receptors (aka mature 
or mutated antibodies) that bind the initial antigen better than the original precursor (germline). Even 
though bN and nN antibodies target the same Env regions, the study found that germline bN 
antibodies recognized Env poorly, while nN antibodies were really good at it. Furthermore, naïve B 
cell progenitors of bN antibodies, in contrast to progenitors of nN antibodies, are not stimulated by 
recombinant Env proteins and do not internalize them. 
In a previously published paper, Dr. McGuire and coworkers showed that disruption of three Env 
glycosylation sites resulted in an increased binding and activation of B cells producing bN 
antibodies. Although the mutated form (glycan deleted) of Env was able to activate B cells producing  
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bN antibodies, it preferentially activated those producing nN antibodies. Following up on these 
findings, the investigators showed that further deletion of the variable loops V1, V2 and V3 (ΔV1-3) 
of the glycan-deleted protein reduces the binding affinity of nN antibodies recognizing the CD4 
binding site of Env and the capacity to activate B cells producing such antibodies. In a mixed culture 
of B cells producing nN, bN and non-Env specific antibodies, the glycan deleted form of Env lacking 
the variable loops stimulated exclusively B cells producing bN antibodies at low concentrations and 
preferentially at high concentrations. 
One of the mechanisms that controls antibody production in germinal centers is a negative feedback 
loop mediated by high affinity antibodies that bind to and mask antigen blocking the activation and 
proliferation of B cells expressing low affinity B-cell receptors (BCRs). Since the affinity of bN 
antibodies (and the BCRs expressed on B cell secreting such antibodies) for the modified form of 
Env is high as compared to that of nN antibodies, bN antibodies should have an advantage when 
such protein is used as an immunogen. Indeed, the presence of nN antibodies decreased the 
activation of bN antibody producing B cells in vitro when the glycan deleted form was used as 
immunogen, but this inhibitory effect was reduced when the variable loops of the protein were 
deleted as well. 
In sum, a series of Env modifications favored the generation of bN antibodies. "We hope that the 
novel immunogen described in the study will perform better than those used in the past, but we'll 
have to get it into people to find out." said Dr. McGuire. "In the current study, we focused on one 
epitope region of Env (the CD4 binding site), but there are many others, and the techniques 
developed in this study can be used to compare the activation of B cell progenitors of broad and 
narrow neutralizing antibodies targeting other regions of Env, or even be applied to vaccine design 
against other pathogens." Needless to say, the results published in this study open the path to a 
novel approach and to previously unexplored possibilities for vaccine research. 
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Image provided by Dr. Andrew McGuire 
The figure summarizes the study. The blue colored B cells are the 
targets that should be stimulated to produce bN antibodies. 
Wildtype Env (top) stimulates everything but the target B cells. The 
glycan deleted Env stimulates the blue B cells but preferentially 
activates the other B cell types (middle). When the variable regions 
are removed as well, the target B cells are preferentially stimulated. 
 
